These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

771 related articles for article (PubMed ID: 22184409)

  • 21. Risk factors predicting outcomes for primary refractory hodgkin lymphoma patients treated with salvage chemotherapy and autologous stem cell transplantation.
    Shah GL; Yahalom J; Matasar MJ; Verwys SL; Goldman DA; Bantilan KS; Zhang Z; McCall SJ; Moskowitz AJ; Moskowitz CH
    Br J Haematol; 2016 Nov; 175(3):440-447. PubMed ID: 27377168
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Brentuximab Vedotin in Transplant-Naïve Relapsed/Refractory Hodgkin Lymphoma: Experience in 30 Patients.
    Zinzani PL; Pellegrini C; Cantonetti M; Re A; Pinto A; Pavone V; Rigacci L; Celli M; Broccoli A; Argnani L; Pulsoni A
    Oncologist; 2015 Dec; 20(12):1413-6. PubMed ID: 26500229
    [TBL] [Abstract][Full Text] [Related]  

  • 23. 18-Fluorodeoxyglucose positron emission tomography/computed tomography for assessment of response to brentuximab vedotin treatment in relapsed and refractory Hodgkin lymphoma.
    Kahraman D; Theurich S; Rothe A; Kuhnert G; Sasse S; Scheid C; Dietlein M; Drzezga A; von Bergwelt-Baildon M; Kobe C
    Leuk Lymphoma; 2014 Apr; 55(4):811-6. PubMed ID: 23805904
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Post-ABVD/pre-radiotherapy (18)F-FDG-PET provides additional prognostic information for early-stage Hodgkin lymphoma: a retrospective analysis on 165 patients.
    Ciammella P; Filippi AR; Simontacchi G; Buglione M; Botto B; Mangoni M; Iotti C; Merli F; Marcheselli L; Bisi G; Ricardi U; Versari A
    Br J Radiol; 2016; 89(1061):20150983. PubMed ID: 27022777
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A 2-step comprehensive high-dose chemoradiotherapy second-line program for relapsed and refractory Hodgkin disease: analysis by intent to treat and development of a prognostic model.
    Moskowitz CH; Nimer SD; Zelenetz AD; Trippett T; Hedrick EE; Filippa DA; Louie D; Gonzales M; Walits J; Coady-Lyons N; Qin J; Frank R; Bertino JR; Goy A; Noy A; O'Brien JP; Straus D; Portlock CS; Yahalom J
    Blood; 2001 Feb; 97(3):616-23. PubMed ID: 11157476
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pre-transplant positron emission tomography (PET) using fluorine-18-fluoro-deoxyglucose (FDG) predicts outcome in patients treated with high-dose chemotherapy and autologous stem cell transplantation for non-Hodgkin's lymphoma.
    Cremerius U; Fabry U; Wildberger JE; Zimny M; Reinartz P; Nowak B; Schaefer W; Buell U; Osieka R
    Bone Marrow Transplant; 2002 Jul; 30(2):103-11. PubMed ID: 12132049
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Improved outcome of patients with relapsed/refractory Hodgkin lymphoma with a new fotemustine-based high-dose chemotherapy regimen.
    Musso M; Messina G; Di Renzo N; Di Carlo P; Vitolo U; Scalone R; Marcacci G; Scalzulli PR; Moscato T; Matera R; Crescimanno A; Santarone S; Orciuolo E; Merenda A; Pavone V; Pastore D; Donnarumma D; Carella AM; Ciochetto C; Cascavilla N; Mele A; Lanza F; Di Nicola M; Bonizzoni E; Pinto A
    Br J Haematol; 2016 Jan; 172(1):111-21. PubMed ID: 26458240
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Brentuximab vedotin administered to platinum-refractory, transplant-naïve Hodgkin lymphoma patients can increase the proportion achieving FDG PET negative status.
    Onishi M; Graf SA; Holmberg L; Behnia S; Shustov AR; Schiavo K; Philip M; Libby EN; Cassaday RD; Pagel JM; Roden JE; Maloney DG; Green DJ; Till BG; Press OW; Smith SD; Gopal AK
    Hematol Oncol; 2015 Dec; 33(4):187-91. PubMed ID: 25236531
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Early FDG-PET assessment in combination with clinical risk scores determines prognosis in recurring lymphoma.
    Schot BW; Zijlstra JM; Sluiter WJ; van Imhoff GW; Pruim J; Vaalburg W; Vellenga E
    Blood; 2007 Jan; 109(2):486-91. PubMed ID: 17003382
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pre-transplant positron emission tomography in patients with relapsed Hodgkin lymphoma.
    Mocikova H; Pytlik R; Markova J; Steinerova K; Kral Z; Belada D; Trnkova M; Trneny M; Koza V; Mayer J; Zak P; Kozak T
    Leuk Lymphoma; 2011 Sep; 52(9):1668-74. PubMed ID: 21699377
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pretransplantation positron emission tomography scan is the main predictor of autologous stem cell transplantation outcome in aggressive B-cell non-Hodgkin lymphoma.
    Derenzini E; Musuraca G; Fanti S; Stefoni V; Tani M; Alinari L; Venturini F; Gandolfi L; Baccarani M; Zinzani PL
    Cancer; 2008 Nov; 113(9):2496-503. PubMed ID: 18833583
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Durable event-free survival following autologous stem cell transplant for relapsed or refractory follicular lymphoma: positive impact of recent rituximab exposure and low-risk Follicular Lymphoma International Prognostic Index score.
    Peters AC; Duan Q; Russell JA; Duggan P; Owen C; Stewart DA
    Leuk Lymphoma; 2011 Nov; 52(11):2124-9. PubMed ID: 21740097
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Phase II study of risk-adapted therapy of newly diagnosed, aggressive non-Hodgkin lymphoma based on midtreatment FDG-PET scanning.
    Kasamon YL; Wahl RL; Ziessman HA; Blackford AL; Goodman SN; Fidyk CA; Rogers KM; Bolaños-Meade J; Borowitz MJ; Ambinder RF; Jones RJ; Swinnen LJ
    Biol Blood Marrow Transplant; 2009 Feb; 15(2):242-8. PubMed ID: 19167684
    [TBL] [Abstract][Full Text] [Related]  

  • 34. High dose chemoradiotherapy and ASCT may overcome the prognostic importance of biologic markers in relapsed/refractory Hodgkin lymphoma.
    Persky DO; Moskowitz CH; Filatov A; Saxena R; Cui H; Teruya-Feldstein J
    Appl Immunohistochem Mol Morphol; 2010 Jan; 18(1):35-40. PubMed ID: 19701081
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Patterns of Failure and Survival Outcomes after Total Lymphoid Irradiation and High-Dose Chemotherapy with Autologous Stem Cell Transplantation for Relapsed or Refractory Classical Hodgkin Lymphoma.
    Paudel N; Schulze D; Gentzler RD; Evens AM; Helenowski I; Dillehay G; Frankfurt O; Mehta J; Donnelly ED; Gordon LI; Winter JN; Mittal BB
    Int J Radiat Oncol Biol Phys; 2019 Jun; 104(2):436-446. PubMed ID: 30763660
    [TBL] [Abstract][Full Text] [Related]  

  • 36. FDG-PET after two cycles of chemotherapy predicts treatment failure and progression-free survival in Hodgkin lymphoma.
    Hutchings M; Loft A; Hansen M; Pedersen LM; Buhl T; Jurlander J; Buus S; Keiding S; D'Amore F; Boesen AM; Berthelsen AK; Specht L
    Blood; 2006 Jan; 107(1):52-9. PubMed ID: 16150944
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Improved survival for relapsed diffuse large B cell lymphoma is predicted by a negative pre-transplant FDG-PET scan following salvage chemotherapy.
    Dickinson M; Hoyt R; Roberts AW; Grigg A; Seymour JF; Prince HM; Szer J; Ritchie D
    Br J Haematol; 2010 Jul; 150(1):39-45. PubMed ID: 20507301
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Combined modality treatment for PET-positive non-Hodgkin lymphoma: favorable outcomes of combined modality treatment for patients with non-Hodgkin lymphoma and positive interim or postchemotherapy FDG-PET.
    Halasz LM; Jacene HA; Catalano PJ; Van den Abbeele AD; Lacasce A; Mauch PM; Ng AK
    Int J Radiat Oncol Biol Phys; 2012 Aug; 83(5):e647-54. PubMed ID: 22607911
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pembrolizumab Added to Ifosfamide, Carboplatin, and Etoposide Chemotherapy for Relapsed or Refractory Classic Hodgkin Lymphoma: A Multi-institutional Phase 2 Investigator-Initiated Nonrandomized Clinical Trial.
    Bryan LJ; Casulo C; Allen PB; Smith SE; Savas H; Dillehay GL; Karmali R; Pro B; Kane KL; Bazzi LA; Chmiel JS; Palmer BA; Mehta J; Gordon LI; Winter JN
    JAMA Oncol; 2023 May; 9(5):683-691. PubMed ID: 36928527
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Interim PET After Two ABVD Cycles in Early-Stage Hodgkin Lymphoma: Outcomes Following the Continuation of Chemotherapy Plus Radiotherapy.
    Simontacchi G; Filippi AR; Ciammella P; Buglione M; Saieva C; Magrini SM; Livi L; Iotti C; Botto B; Vaggelli L; Re A; Merli F; Ricardi U
    Int J Radiat Oncol Biol Phys; 2015 Aug; 92(5):1077-1083. PubMed ID: 26031367
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 39.